Dr. Reddy’s signs licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
The special financing terms offered by United Imaging and structured by Medikabazaar to Krsnaa Diagnostics underscore the strategic importance of this alliance
Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia
India called for stronger investments in health and social equity at G20 Joint Finance-Health Task Force Meeting
Global survey reveals top workforce concerns, evolving strategic priorities, and key technology investment areas for life sciences manufacturers
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
The mobile unit "Breast Health Express" brings advanced medical technology directly to communities in need
The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg
Subscribe To Our Newsletter & Stay Updated